Introduction
Neuro®bromin (NF) is thought to function as a tumor suppressor at least in part through its GTPase activity. The loss of NF function is believed to be a critical event in the pathogenesis of neuro®bromatosis type 1 (NF1) (DeClue et al., 1991 (DeClue et al., , 1992 Gutmann et al., 1991;  for review see Bernards, 1995) . NF1 is a common autosomal dominant disorder (incidence 1 : 3500) characterized by numerous abnormalities, including changes in neural crest derivatives such as Schwann cells and melanocytes that result in hamartomas of the iris (Lisch nodules), cafeÂ -au-lait macules, and multiple, benign, peripheral neuro®bromas (Gutmann and Collins, 1995) . NF1 patients are also at greatly increased risk for malignant peripheral nerve sheath tumors (MPNST), derived from Schwann cells, ®broblasts, or both (Zoller et al., 1997) . Schwann cells isolated from human neuro®bromas are angiogenic in the chick chorioallantoic membrane (CAM) assay, while normal Schwann cells are not (Sheela et al., 1990) . Furthermore, Schwann cells isolated from neuro®bromin-de®cient knockout mice are also angiogenic in a CAM assay, while wild type cells are not (Kim et al., 1997) . In contrast, ®broblasts isolated from NF1 knockout embryos or from neuro®-bromas are not angiogenic in the same assays. It is thus suggested that neuro®bromin suppresses the expression of angiogenic factors in Schwann cells.
Although rarely occurring in the quiescent vasculature of the adult, angiogenesis has been shown to be a central event in the growth of tumors (for review see Folkman, 1995) . There are numerous growth factors capable of inducing angiogenesis, including ®broblast growth factors (FGFs) (Friesel and Maciag, 1995) , vascular endothelial growth factor (VEGF) (Ferrara et al., 1996) , pleiotrophin (PTN), midkine (MK) (Zhang and Deuel, 1999) and others (reviewed in Carmeliet and Jain, 2000) . The expression pattern of angiogenic inducers and inhibitors appears to be closely linked with both oncogenes and tumor suppressor genes (Hanahan and Folkman, 1996) . In a similar manner, loss of the tumor suppressor neuro®bromin might lead to an angiogenic phenotype due to the induction of growth factors.
Neuro®bromin acts as a ras-GTPase activating protein (rasGAP) (Xu et al., 1990) ; its downregulation in NF1 elevates activated ras levels (DeClue et al., 1992; Kim et al., 1995) and might subsequently result in aberrant regulation of growth factors (Vogel et al., 1995) . A number of growth factors and growth factor receptors are expressed in neuro®bromas. It is not known, however, if speci®c changes in growth factor expression are primarily the result of NF1 loss or are triggered by secondary genetic events which occurred during neuro®broma development. A further alternative is that upregulated factors are derived from blood and other non-tumor material.
The current study investigates the molecular mediators of neuro®broma angiogenesis and growth. In particular, we focus on the expression, distribution, and function of MK in the tumors of NF1. The 13 kD heparin binding, secreted MK shows 45% amino acid homology, complete conservation of all ten cysteine residues and of the putative heparin binding site to the only other protein family member pleiotrophin (PTN) (Kretschmer et al., 1991; Tsutsui et al., 1991) . MK and PTN are highly conserved during evolution and their rigid three dimensional structure predicts two domains with perhaps distinct function (Iwasaki et al., 1997) . MK and PTN have been shown in vitro to promote neurite outgrowth (Kaneda et al., 1996) , neuronal dierentiation, neuronal survival (Kikuchi et al., 1993) and tumor angiogenesis (for review see Kurtz et al., 1995; Zhang and Deuel, 1999) . Downregulated in most tissues in the adult, nervous system expression of MK remains in the cerebellum, whereas PTN persists in the cortex, hippocampus and cerebellum (Bloch et al., 1992; Nakamoto et al., 1992; Matsumoto et al., 1994; Vanderwinden et al., 1992) . MK has been found to be induced in a variety of tumors (Garver et al., 1994; Nakagawara et al., 1995; O'Brien et al., 1996; Kato et al., 1999) . We have previously shown the selective upregulation of MK in the skin of NF1 patients (Mashour et al., 1999) .
Here we report the dierential expression of MK mRNA and protein in NF17/7 mouse Schwann cells, human neuro®bromas, MPNST and related peripheral and central nervous system tumors. Finally, we demonstrate that MK can function not only as a mitogen for systemic endothelial cells, but also for CNS-derived endothelial cells, MPNST and neuro®-broma-derived cells.
Results

NF17/7 Schwann cells differentially express angiogenic modulators
To determine whether NF17/7 Schwann cells induce angiogenesis by secreting growth factors for endothelial cells, we collected conditioned medium from NF17/7, NF+/7 and NF1+/+ puri®ed Schwann cells isolated from cultured embryonic day 12.5 murine dorsal root ganglia (DRG) (Kim et al., 1997) . Aliquots of the conditioned media were added to human umbilical vein endothelial cells (HUVEC) and cell number was determined after 48 h. As controls, unconditioned medium and the potent endothelial cell mitogen FGF-2 were used (Figure 1 ). Conditioned medium from NF17/7 cells strongly stimulated proliferation of endothelial cells; this stimulation was comparable to that obtained with FGF-2. In contrast, conditioned medium from NF1+/7 and from NF1+/+ cells inhibited proliferation of endothelial cells when compared to unconditioned medium.
The stimulatory eect of factors induced and secreted after loss of neuro®bromin in NF17/7 cells could be due to suppression of angiogenic inhibitors or to activation of angiogenic stimulators. In order to investigate possible mediators of angiogenic activity in murine neuro®bromin-de®cient Schwann cells, we screened for dierential expression of known angiogenic factors by RT ± PCR. We initially focused on factors that are reportedly expressed in neuro®bromas, and extended the study for members of the PTN-family of growth factors. Furthermore, we screened for expression of the angiogenic inhibitor thrombospondin-1 (TSP-1). Because many other angiogenic inhibitors are cleavage products of larger proteins, they could not be identi®ed by the applied method. RNA was isolated from Schwann cells derived from NF17/7 and wild type embryonic day 12.5 murine DRG, and transcription of angiogenic factors was evaluated ( Figure 2) . Our results indicate a shift in the angiogenic pro®le due to neuro®bromin loss (Table 1) . TSP-1, FGF-2, plateled derived growth factor beta (PDGF), MK, and an mRNA splice variant of MK were all detected in NF17/7 Schwann cells but not in NF1+/+ cells. PTN mRNA was expressed in both NF17/7 and wild type cells whereas transcripts for Figure 2 Detection of growth factor expression from NF17/7 and NF1+/+ RNA by RT ± PCR. RT ± PCR products were detected by Ethidiumbromide staining. RNA from NF7/7 cells (7) and NF+/+ (+) murine Schwann cells was analysed for transcripts of the dierent factors Figure 1 Eects of conditioned media from NF17/7, +/7 and +/+ Schwann cells on the proliferation of HUVEC. P50.0001 (between NF17/7 and +/+) and P50.002 (between NF17/7 and +/7). Medium conditioned by equal numbers of NF17/7, +/7 and +/+ Schwann cells was diluted 1 : 2 in unconditioned medium and added to HUVEC cells for 3 days insulin like growth factor-2 (IGF2), VEGF, hepatocyte growth factor (HGF), and FGF-1 were not detected in cells of either genotype. Neuro®bromin, b-Actin, the glial and Schwann cell brain fatty acid binding protein (bFABP) and neuronal hFABP expression were used as controls ( Figure 2 , Table 1 ). RNA derived from whole mouse embryos (e 13) were used as positive controls for growth factor expression (not shown).
To detect and quantify MK-protein expression and secretion by NF17/7 and NF1+/+ mouse Schwann cells, an ELISA assay speci®c for MK and a detection limit of 5 pg (0.5 ng/ml) was performed. MK was only detected in NF17/7 cells at a concentration of 1.0 ng/ ml conditioned medium. No MK protein was detected in medium conditioned by NF1+/+ Schwann cells (data not shown).
MK is expressed in tumors of NF1 and NF2
Since MK is a factor with restricted expression in the adult, and is upregulated in a number of tumors (see Kurtz et al., 1995) , we screened for its expression in human nervous system tumors by Northern blot analysis. Expression of MK was compared with its homolog PTN.
Our results show that MK mRNA is expressed in neuro®bromas as well as malignant peripheral nerve sheath tumors (MPNST) (Figure 3a) . Noteable is the expression of a malignancy associated truncated mRNA splice form of MK in three out of four MPNSTs, but in none of the benign neuro®bromas. High expression of MK was also found in schwannomas, meningiomas, and astrocytomas, but not in normal brain cortex (Figure 3b ). Two human neuro®-broma derived cell lines, which did not express neuro®bromin as determined by RT ± PCR and were of ®broblast morphology (Hs422T, Hs53T) expressed MK at very low levels, whereas the MPNST derived ST8814 cells was found to be strongly positive for MK ( Figure 3c ). PTN showed a similar pattern but expression was detected in fewer tumors than MK. The expression data are summarized in Table 2 .
Localization of MK expression in tumors of NF1
Neuro®bromas are composed of a mixture of Schwann cells, ®broblasts, perineurial cells, mast cells and endothelial cells, with Schwann cells usually constituting the majority. In order to determine which cell type expresses MK within the tumors, we performed in situ hybridization (ISH) and immunohistochemistry for MK, its homolog PTN, and the Schwann cell marker S-100. Tissue sections from dermal neuro®bromas, plexiform neuro®bromas and malignant peripheral nerve sheath tumors (MPNST) were analysed.
Whereas PTN is barely detectable in dermal neuro®bromas by immunohistochemistry, MK and S-100 are both highly expressed (Figure 4a ± f). In contrast to intracellular and nuclear S-100 expression, the secreted MK appears more diusely distributed (Figure 4e ,f). Although PTN is occasionally expressed in the skin overlaying dermal neuro®bromas, only MK was consistently found in the skin of NF1 
Expression analysis of the dierent factors was by RT ± PCR using mRNA from null (NF7/7), and wild type (NF+/+) DRG-derived day 12.5 embryonic mouse Schwann cells (Table 1) , demonstrating MK upregulation in NF1 mutated cells.
To test if MK is expressed by Schwann cells within the tumors of NF1 patients, we performed double immuno¯uorescence staining of plexiform neuro®bro-mas and MPNST with S100 and anti-MK antibodies. The majority of S-100 positive cells showed staining for MK. Thus MK expression is correlated with S-100 positive cells in NF1 derived plexiform neuro®bromas (n=2) and MPNST (n=2) (Figure 5a ± c) . No other cells except blood vessels were found positive for MK within the tumors. By closer examination of blood vessel using in situ hybridization, we found MK mRNA expression localized to the endothelial cells (Figure 5d ). Blood vessels and endothelial cells from normal, non tumorigenic tissue were negative for MK expression as were sections hybridized with sense MK probes (not shown). mRNA expression for PTN and MK correlated with protein expression in all the tissues analysed.
MK is a mitogen for brain endothelial cells and neurofibroma derived cells
Expression and secretion of MK by Schwann cells and endothelial cells has the potential for paracrine and autocrine stimulation of neuro®broma growth. We studied the mitogenic activity and colony formation of the MPNST derived cell line ST8814, brain derived endothelial cells (HBEC), and ®broblastoid cell line Hs422T with and without MK. ST8814 cells, which express high levels of MK mRNA, were not stimulated to proliferate by external addition of MK. In contrast, MK acted as a strong mitogen for HBEC cells ( Figure  6a ). In Hs422T cells, which express only low MK mRNA levels, colony formation was induced about four times compared to controls in agreement with earlier results showing that MK stimulates proliferation of Hs422T monolayers about twofold (Mashour et al., 1999) .
To test whether MK is a mitogen for ST8814 cells, we designed antisense oligonucleotides for MK to downregulate its endogenous expression. Treatment of ST8814 and of Hs422T cells with 10 mg/ml MKantisense oligonucleotides resulted in a maximal reduction of MK mRNA levels by 37% (Figure 6b ). Increasing oligonucleotide concentrations did not result in further reduction of transcript. Reduction of MK mRNA levels in ST8814 cells treated with MKantisense oligonucleotides led to inhibition of proliferation and colony formation in soft agar by more than 30%, when compared to control cells treated with sense oligonucleotides. Downregulation of the already low MK mRNA levels, however, did not inhibit proliferation in Hs422T cells (Figure 6c ).
Discussion
It is now well established that a switch to an angiogenic phenotype is a requirement for the growth of tumors beyond several millimeters (Folkman, 1995) . Angiogenesis is likely to be critical for neuro®broma growth, as neuro®bromas can grow to huge (kilogram) sizes in NF1 patients. Human and murine neuro®-bromin-de®cient Schwann cells have been shown to promote angiogenesis (Sheela et al., 1990; Kim et al., 1997) , but the molecular mediators of this switch have not previously been characterized. Our results suggest a shift in the angiogenic pro®le of murine Schwann cells due to loss of neuro®bromin expression. Expression of PDGF, FGF-2, and MK growth factors was induced in NF17/7 Schwann cells. To what extent each individual factor found in NF17/7 Schwann cells contributes to the angiogenic switch and to the observed stimulation of endothelial cell proliferation remains to be elucidated. The low concentration of MK in conditioned media of NF17/7 Schwann cells and the robust stimulation of endothelial cells suggest that MK is only one among several molecules necessary to switch the angiogenic balance. Interestingly, studies in other systems suggest that shifting the angiogenic balance by eliminating only one stimulator is at least temporarily sucient to suppress tumor growth (Schulte et al., 1996) . In addition to angiogenic stimulators, the angiogenic inhibitor TSP-1 was expressed in knock-out but not normal Schwann cells, suggesting a compensatory shift in the angiogenic pro®le. A comparable upregulation of TSP-1 has been described in VEGF-expressing cancer samples and in adjacent stroma cells (Salvesen and Akslen, 1999; Ohtani et al., 1999; Tuszynsky and Nicosia, 1996) . Interestingly, NF1+/+ and NF1+/7 Schwann cells may secrete factors inhibiting proliferation of endothelial cells because conditioned media from these cells stimulated endothelial cell proliferation less eectively than unconditioned control media. The identity of potential angiogenesis inhibitors is not known, but their downregulation in NF17/7 cells in addition to upregulation of angiogenic stimulators might equally contribute to endothelial cell activation.
MK and its homolog PTN show dierential expression in neuro®bromas. PTN is expressed in NF1+/+ and NF17/7 cell types and in normal sciatic nerve Schwann cells, as well as at low levels in dermal neuro®broma and MPNST. Expression of MK on the other hand was restricted to NF17/7 Schwann cells and co-localized with S-100-positive cells in human neuro®bromas; MK was not detected in normal sciatic nerve Schwann cells.
The co-expression of PTN and MK has been suggested to be of potential pathophysiologic signi®-cance (Garver et al., 1994) , as the expression of both members of this growth factor family might result in synergistic eects supporting neuro®broma growth. Although little is known about hormonal regulation of MK, PTN is hormonally regulated (Milhiet et al., 1998) , and a possible hormonal upregulation of PTN in neuro®bromas in conjunction with constitutionally high tumor MK levels might support the preferential growth of neuro®bromas during puberty and pregnancy (Dugo and Sujansky, 1996) .
It is also of interest to note that an RNA splice variant of MK that is dierentially expressed in malignant tumors (Kaname et al., 1996) is expressed in NF17/7 Schwann cells as well as human MPNSTs. Expression of truncated MK was not demonstrated in benign neuro®bromas, and thus may be an indicator for malignant transformation of these tumors.
There is growing evidence for the role of MK as a paracrine and autocrine angiogenic factor Choudhuri et al., 1997) , and our data support these recent ®ndings (Mashour et al., 1999) . Here we show that MK is also a potent mitogen for nervous system derived endothelial cells and stimulates anchorage independent growth of neuro®broma derived Hs422 ®broblasts and MPNST derived ST88-14 cells, possibly of Schwann cell origin. Neuro®bromas consist of several cell types including mast cells, perineural cells, ®broblasts and Schwann cells, the last two usually providing the majority. The MK expressed by S-100 positive Schwann cells within the tumor could support this type of mixed cell growth by aecting endothelial cells, ®broblasts and Schwann cells and thus contribute not only to angiogenesis but also tumorigenesis of neuro®bromas. It is of interest to note that FGF-2, which was also upregulated in NF17/7 Schwann cells, is present in some neuro®bromas , and stimulates Schwann cell proliferation and survival (Chen et al., 1991; Gavrilovic et al., 1995; Schubert, 1992) . PDGF, also upregulated in NF17/7 Schwann cells, has been proposed to contribute to MPNST growth (Badache and DeVries, 1998) .
In addition to tumors characteristic of NF1, MK was shown to be expressed in tumors characteristic of neuro®bromatosis type 2 (NF2), including vestibular schwannomas and schwannomas from patients with schwannomatosis and meningiomas. Expression was also shown by Northern blot in meningiomas and con®rmed for astrocytomas (Mishima et al., 1997) , both of which have a higher incidence in neuro®bro-matosis. Thus MK expression may be a frequent feature of PNS and CNS tumors and stands in contrast to the low or absent expression of MK in normal brain and nerve.
In conclusion, our data suggest that MK could promote neuro®broma formation by its expression pattern and angiogenic and mitogenic properties, and that MK expression is directly linked to mutations in the NF1 gene in Schwann cells.
Materials and methods
RT ± PCR
RNA was isolated from about 0.5610 6 NF17/7 or NF1+/+ Schwann cells (methods for isolation of Schwann cells described in Kim et al., 1997) . For positive control PCRreactions, total RNA from 13 day old normal mouse embryos was used and all mRNA species were detected. Eight mg RNA were used for reverse transcription with random hexanucleotide primers and Superscript (Gibco ± BRL) reverse transcriptase. The cDNA was diluted in 100 ml water and 3 ml were used for each PCR reaction (30 cycles, each 30 s denaturation at 948C, 30 s annealing at 558C, 1.5 min polymerization at 728C. Fifty per cent of the reaction samples were analysed on a 3% Metaphor agarose gel. Speci®c regions for FGF-1 and FGF-2, PTN, MK, truncated MK (MK-t), PDGF-B, VEGF-b, HGF, IGF-2, TSP-1, bFABP, hFABP, b-actin, and neuro®bromin were ampli®ed. bFABP and hFABP are markers for glia and Schwann cells and neuronal cells, respectively (Kurtz et al., 1994) . Primer sequences are as follows 5' to 3'. VEGF-b: 1. CCTGTGTCCCAGTTTGAT, 2. TGGCTGTGTTCTTCC-TGG; FGF-2: 1. ATGGCTGCCAGCGGCATC, 2. ATTA-GATTCCAGTCGTTC; FGF-1: 1. CTGAAGGGGAGAT-CACAA, 2. CTAGTCAGAAGACACCGG; PDGF-b: 1. GG-AGTTGATCGAGCGGCT, 2. GTATGTTCAGGAATGT-CA; MK: 1. GATAAGGTGAAGAAGGGC, 2. CTCCTTG-GCATCCAGGCT; PTN: 1. CCAGCAATATCAGCAGCA, 2. TTGACTCCGCTTGAGGCT; HGF: 1. AACTTCTGCC-GGTCCTG, 2. GATCATGGAATTCCAAGG; IGF-2: 1. GAAAGTCGATGTTGGTGC, 2. AGCAGCGATGCAG-CACAA; bFABP: 1. GACTCTCACTCATGGCAGTGT, 2. GAGCACCCTTTCCATACAGTT; hFABP: 1. AAAGAG-GCTGTCCAGCCGGGA, 2. CCGAGTGACTTCATGTAG-TCA; TSP-1: 1. GGACTAGGTGTCCTGTTC, 2. GACAC-CACTTGTTGCTTC; MK-t: 1. ATGCAGCACCGAGGC-TTC, 2. CTGACTTAGTCCTTTCCT; Neuro®bromin: 1. AGTGGCTTGCAATGTTCG, 2. GGTCCTAAACGTTTC-GCA.
Elisa
MK protein detection was performed using a sensitive and speci®c ELISA assay kit as described (Ikematsu et al., 2000) , which was kindly provided by Dr Sadatoshi Sakuma (Meiji Milk Products, Japan). Detection limit for MK using this assay is 5 pg (0.5 ng/ml). 10 ml from a total of 1 ml conditioned serum free medium of 10 6 NF17/7 and NF1+/+ cells were used for detection. MK concentration standard was full-length synthetic MK peptide preparation (Peptide Institute, Osaka, Japan) at 0, 0.5, 1, 2, 3 and 4 ng/ml.
Tissues and cell lines
Neuro®broma, MPNST and schwannomatosis tumor samples were the generous gift of Dr Mia MacCollin from the Massachussets General Hospital, while other tumor samples and normal tissues were obtained from neurosurgical cases at Georgetown University Hospital and from the Lombardi Cancer tissue bank. Neuro®broma derived cell lines Hs422T and Hs53T were obtained from American Tissue Type Culture (ATCC). ST8814 cells and HUVEC were obtained from the Lombardi Cancer Center cell culture core. HBEC cells were isolated from brain tissue obtained from epilepsy surgery as described (Costello and DelMaestro, 1990) . SW-13, SW-13 transfected with an empty pRC/CMV control vector, and SW-13 transfected with pRC/CMV-human MK expression construct (MK6) are described (Mashour et al., 1999) .
Northern analysis
For Northern blots, RNA was isolated from each tissue or tumor cell line using RNA-Stat and 20 mg were separated in a denaturing agarose gel, and blotted onto nylon membrane. Blots were hybridized with an a-32 P-dCTP-labeled cDNA probe prepared by random primed DNA labeling (Amersham) of the full-length human MK cDNA, washed, and then autoradiographed with intensifying screens at 7708C for 48 h. Equal loading was controlled by ethidium bromide staining and con®rmed by gluceraldehyde-3-phosphate dehydrogenase (GPDH) hybridization.
In Situ hybridization (ISH)
Sense and antisence digoxigenin-labeled (Boehringer Mannheim) riboprobes for human MK and FGF-2 were transcribed in vitro from 1 mg of linearized plasmid DNA, treated with RNase-free DNase I, precipitated and washed, and resuspended in 100 ml DEPC-treated water. Paran embedded tissue sections for dermal neuro®bromas, plexiform neuro®bromas, MPNST, and skin were obtained from the Lombardi Cancer Center Tumor Bank. ISH was essentially performed as described (Panoskaltiss-Mortari and Bucy, 1995) . Brie¯y, 6 mm thick tissue sections on silanized slides were washed, acetylated, and treated overnight at 558C with hybridization solution (26SSC, 50% formamide) containing heat-denatured sense or antisense riboprobes. The following day, sections were washed at high stringency twice for 20 min at 538C in 26SSC, 50% formamide, rinsed in 26SSC at room temperature, incubated in RNAse A (100 mg/ml) for 30 min at 378C and washed again. Subsequently, slides were stained with an alkaline phosphatase-conjugated sheep-anti-digoxigenin antibody (Boehringer Mannheim). Chromagen substrate for alkaline phosphatase (NBT/BCIP) was added and the reaction was allowed to proceed overnight at 48C. Color development was stopped with 10 mM Tris-HCl, pH=8.0, 1 mM EDTA and tissue was mounted in an aqueous mounting medium.
Immunohistochemistry
Paran-embedded neuro®broma, PNST, MPNST, and normal sciatic nerve tissue sections were microwaved for 10 min and after 5 min cooling at room temperature were treated with fresh xylene for 10 min. After two washes in 100% ethanol for 5 min each, the slides were rehydrated by gradient ethanol washing and then washed in ddH 2 O and PBS for 1 min each. Microwave treatment was performed in PBS/1% (v/v) acetic acid for 10 min reaching 808C. The slides were cooled and washed twice in PBS. The tissue was then treated with PBS/1% BSA and blocked for 30 min with 20% normal serum in PBS. Normal serum of the species in which the respective antibodies were produced were used for blocking. For MK staining, after washing in PBS/1% BSA for 5 min, primary antibody against MK (1 : 100, Santa Cruz Biotechnology), S-100 (1 : 200, NeoMarkers), PTN (1 : 20, Research Genetics), respectively, were applied for at least 1 h at room termperature. After three washes in PBS, slides were blocked for 30 min with 20% normal serum in PBS. Secondary antibody conjugated to biotin, rhodamine (MK) or¯uorescein (S-100), respectively, were applied for at least 20 min. Slides were washed three times in PBS. Detection for biotin was by incubation with ABC-reagent (Vector) for 15 min followed by 3,3' diaminobenzidine (DAB) staining before slides were mounted. For double immuno¯uorescence, tissues were ®rst incubated with anti-MK antibodies, washed after secondary antibody incubation, and the protocol was repeated using a primary antibody against S-100 and a secondary conjugated to¯uorescein.
Proliferation assays
HUVEC were plated at 1000 cells/well in a ®bronectin coated 96-well plate in 100 ml IMEM/10% FBS. After 16 h, 100 ml of serum free media (negative control), media supplemented with 6 ng/ml FGF-2 (positive control) and 100 ml of media conditioned by NF17/7, +/7 or +/+ murine Schwann cells and normalized for cell number were added in triplicate. Embryonic Schwann cells were isolated, cultured and puri®ed as described (Kim et al., 1997) .
For MK proliferation assays, MK from conditioned medium of MK producing SW13-MK and MK negative SW13-pcDNA cells was partially puri®ed: 100 ml of media conditioned for 24 h by SW-13 cells (wild type or MKtransfected MK6 cells) were loaded onto 1 ml heparinSepharose columns (Pharmacia Biotech Inc.), washed and the bound proteins were eluted with a step gradient of 3 ml each of 0.4 M, 0.9 M and 2.0 M NaCl in 10 mM Tris buer (pH 7.5) as described (Mashour et al., 1999) . Equal aliquots of eluate were added to the culture media or soft agar to reach a ®nal MK concentration of 10 ng/ml. HBEC, ST8814 and Hs422T cells were plated in 24-well plates using 1 ml of growth media (®bronectin coated plates for HBEC) and MK or control was added 16 h later. After 3 days the cells were trypsinized and counted in a particle counter (Coulter Conter ZM). For antisense experiments, phosphothioate stabilized MK sense and antisense oligonucleotides were designed from nucleotides 74 ± 94 of the human MK mRNA and synthesized. Sequences are as follows: Sense: 5'-GCCCCTTC-TTCACCTTATCTT-3', Antisense: 5'-AAGATAAGGT-GAAGAAGGGC-3' Oligonucleotides were resuspended in phosphate buered saline (PBS). Antisense oligonucleotides were mixed with lipofectamine and added to cells at a ®nal concentration of 10 mM. Cells were incubated for 2 days and on the morning of the third day, the media were replaced with 100 ml IMEM/10% FBS+10 ml WST-1 colorimetric reagent (Boehringer). Beginning at 30 min after addition of reagent, plates are read at a reference l of 600 nm and test l of 450 nm. For colony formation assays in soft agar, 6% agar (Difco) in medium (IMEM, 10% FCS) was plated in 35 mm dishes as bottom layer. 5610 3 ST8814 or Hs422T cells were mixed with 3.6% agar as top layers and plated on top of the solidi®ed bottom agar. Cells were cultured at 378C and 5% CO 2 in the presence or absence of 10 ng/ml MK. For antisense experiments, cells were incubated with oligonucleotides for 24 h before plating in soft agar. Colonies were counted after 2 weeks using a colony counter (Omnicon 3600 Image analysis). All experiments were performed at least in triplicate.
